

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Beijing Biostar Pharmaceuticals Co., Ltd.**

**北京華昊中天生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2563)**

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO EXPECTED QUALIFIED OPINION**

Reference is made to the announcement of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) dated 25 March 2026 in relation to expected qualified opinion (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The board of directors (the “**Board**”) of the Company wishes to provide further information to the shareholders and potential investors that the Auditors may issue a qualified opinion due to recoverability of an investment fund.

The Company is in discussions with the Auditors to address the relevant issues. Further details will be disclosed in the Annual Results announcement.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Beijing Biostar Pharmaceuticals Co., Ltd.**  
北京華昊中天生物醫藥股份有限公司  
**Dr. Tang Li**  
*Chairman and Executive Director*

Beijing, the PRC, 25 March 2026

*As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.*